April 23, 2025 — Laekna (2105.HK) a science-driven, clinical-stage biotechnology company, released its 2024 Environmental, Social and Governance (ESG) report.

In 2024, Laekna's ESG rating has soared from B+ to A-. The significant advancements we’ve achieved in the past year stem from the synergy of innovation spirit, know-how experience, efficient execution, and humanistic care under the guidance of ESG-driven corporate philosophy. We accelerated clinical trials at full speed while continuing to focus on internal discovery of our drug candidates in metabolic diseases and cancer area. We also actively engaged in the global biopharmaceutical collaboration network.

“The past year marked a pivotal year for "Laekna's ESG digital empowerment", said Dr. LU Chris Xiangyang, Chairman and CEO of Laekna.

• Laekna achieved standardized and transparent governance by launching the OA system and QMS (Quality Management System)
• At the corporate culture level, digitization conveys positive energy
• In fulfilling social responsibilities, digitization transcends geographical barriers

“If ESG is the cornerstone of a company's sustainable development, then digital empowerment is an engine driving Laekna forward, making R&D more efficient, management more transparent, culture more cohesive, and responsibility more tangible.” Dr. LU stated.

Laekna’s ESG Performances Highlights

Governance

• Upgraded the Office Automation (OA) system, improving efficiency and enhancing collaboration
• Communicated with stakeholders, including investors and shareholders, guided by a transparent, honest, timely, and professional approach
• Took steps to integrate ESG values into Laekna’s partnerships, aiming to build a resilient, low-risk, and responsible supply chain

Innovative R&D

• Implemented a series of initiatives to strengthen R&D capabilities, including an AI-driven drug discovery platform
• Established a three-tiered structure comprehensive pharmacovigilance system to identify, evaluate, report and address potential safety risks
• Filed over 30 patent applications across various jurisdiction

Focusing on Talent

• Launched Laekna Land online as a values-driven recognition and motivation platform, over 120 employees have received recognition at different levels
• Provided lactation rooms for pregnant and nursing employees, offering safe, hygienic, and private spaces to create a maternity-friendly workplace environment
• Formulated a series of measures, including the Laboratory Biosafety Management System to protect employees' health and safety

Green Operation

• Identified the six types of climate risks and preliminarily completed the identification, assessment, prioritization, and qualitative financial impact analysis of climate risks
•  Mapped our value chain to understand how climate risks impact current and anticipated business modes
•  Investigated a range of operational methods to minimize the generation of hazardous waste in the laboratory

Community Engagement

• Partnered with the non-profit organization Trash Running to co-host a volunteer trash collection activity
• Consistently advanced the "Children's Science Innovation Classroom" initiative in Gansu Province to enhance science education philanthropy
• Launched the "ESG Quick Fill" mini program on internal OA system to facilitate and incentivize employees to participate in volunteer activities

-  End –

Contact Us

IR  ir@laekna.com

Media  communication@laekna.com

Corporate and Business Development  BD@laekna.com

About Laekna

Stock Code: 2105.HK

Founded in 2016, Laekna is a science-driven, clinical-stage biotechnology company committed to bringing novel therapeutics to patients with metabolic diseases, cancer and liver fibrosis around the world.

As of December 31, 2024, Laekna has initiated seven clinical trials for LAE102, LAE002 (afuresertib), LAE001 and LAE005 to address unmet medical needs in obesity and cancers.

LAE102 is our internally discovered antibody against ActRIIA. Blocking Activin-ActRII pathway could promote muscle regeneration and decrease fat mass, this positions LAE102 as a promising drug candidate for achieving quality weight control. We’ve obtained IND approvals from the FDA and the CDE for LAE102 in obesity indication and are advancing the Phase I clinical trial in China. In November 2024, Laekna entered into a clinical collaboration agreement with Eli Lilly and Company to support and accelerate global clinical development of LAE102 for the treatment of obesity.

Laekna team has accumulated tremendous experiences and deep know-how in the specific field of targeting ActRII receptors and is developing more drug candidates (LAE103 and LAE123), in addition to LAE102, to maximize the value of the target. LAE103 is an ActRIIB-selective antibody and LAE123 is a dual inhibitor against ActRIIA/IIB. Both are our internally discovered antibodies for muscle and other disease indications.

In the cancer area, Laekna has built a comprehensive portfolio of drug candidates including LAE002(afuresertib), LAE001 and other seven pre-clinical drug candidates. LAE002 (afuresertib) is a potent AKT inhibitor that inhibits all three AKT isoforms (AKT1, AKT2 and AKT3) as well as one of the only two AKT inhibitors in late-stage development for breast and prostate cancer globally. Laekna has commenced the Phase III clinical trial (AFFIRM-205) for LAE002 in patients with HR+/HER2- breast cancer and the study recruitment is on track.

Laekna, Inc. (2105.HK) was listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”) on June 29, 2023.

For more information, please visit: https://www.laekna.com/  or https://www.linkedin.com/company/74110713/

Forward-Looking Statements

This press release may contain certain “forward-looking statements” which are not historical facts, but instead are predictions about future events based on Laekna’s current beliefs, assumptions and expectations, commonly identified by words such as "would", "may", "expects", "believes", "plans", "intends", "projects" and other terms with similar meaning. Although we believe that our predictions are reasonable, future events are inherently uncertain and our actual future results or performance may be materially different from what we expect. Accordingly, you are strongly cautioned that reliance on any forward-looking statements is subject to significant known and unknown risks and uncertainties. All forward-looking statements contained herein are qualified by reference to the cautionary statements set forth in this section. All information provided in this press release is as of the date of this press release and are based on assumptions that we believe to be reasonable as of this date, and we do not undertake any obligation to update any forward-looking statement, except as required under applicable law.